Clinical Trial Update: Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and tolerability of durvalumab plus tremelimumab with FOLFOX in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• FOLFOX
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Centre Georges Francois Leclerc | Conditions: Colorectal Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED